Leeward Investments LLC MA Sells 3,293 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Leeward Investments LLC MA lowered its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 3.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 94,287 shares of the medical equipment provider's stock after selling 3,293 shares during the quarter. Leeward Investments LLC MA's holdings in Zimmer Biomet were worth $10,671,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Garde Capital Inc. acquired a new stake in shares of Zimmer Biomet in the first quarter valued at about $29,000. Washington Trust Advisors Inc. acquired a new position in Zimmer Biomet during the first quarter worth approximately $30,000. Menard Financial Group LLC acquired a new position in Zimmer Biomet during the fourth quarter worth approximately $30,000. Accredited Wealth Management LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at approximately $36,000. Finally, OFI Invest Asset Management bought a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $40,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on ZBH shares. BTIG Research restated a "buy" rating on shares of Zimmer Biomet in a research note on Monday, April 14th. JPMorgan Chase & Co. decreased their price objective on shares of Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating on the stock in a report on Tuesday, May 6th. Royal Bank Of Canada cut their target price on shares of Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. The Goldman Sachs Group reduced their target price on shares of Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating for the company in a report on Tuesday, May 6th. Finally, Stifel Nicolaus set a $115.00 price target on shares of Zimmer Biomet and gave the company a "buy" rating in a report on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $111.33.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of the firm's stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total value of $95,000.00. Following the sale, the insider owned 20,424 shares of the company's stock, valued at approximately $1,940,280. This trade represents a 4.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.39% of the company's stock.

Zimmer Biomet Price Performance

ZBH traded up $0.17 on Friday, hitting $93.67. 927,032 shares of the stock were exchanged, compared to its average volume of 1,808,334. The firm has a market capitalization of $18.53 billion, a price-to-earnings ratio of 11.90, a PEG ratio of 2.17 and a beta of 0.71. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.44 and a quick ratio of 1.46. Zimmer Biomet Holdings, Inc. has a 12 month low of $89.22 and a 12 month high of $116.71. The business has a 50-day moving average of $94.20 and a two-hundred day moving average of $101.88.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. The company had revenue of $1.91 billion during the quarter, compared to analysts' expectations of $1.89 billion. Zimmer Biomet had a net margin of 11.86% and a return on equity of 12.73%. The business's revenue for the quarter was up 1.1% compared to the same quarter last year. During the same period in the previous year, the company earned $1.94 EPS. Sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.02%. The ex-dividend date of this dividend is Thursday, June 26th. Zimmer Biomet's dividend payout ratio is presently 21.24%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.